[go: up one dir, main page]

HN2010000203A - DERIVATIVES OF N- (ARILAMINO) SULFONAMIDS THAT INCLUDE POLYMORPHES AS MEK INHIBITORS AS WELL AS COMPOSITIONS, METHODS OF PREPARATION USE OF THE SAME. - Google Patents

DERIVATIVES OF N- (ARILAMINO) SULFONAMIDS THAT INCLUDE POLYMORPHES AS MEK INHIBITORS AS WELL AS COMPOSITIONS, METHODS OF PREPARATION USE OF THE SAME.

Info

Publication number
HN2010000203A
HN2010000203A HN2010000203A HN2010000203A HN2010000203A HN 2010000203 A HN2010000203 A HN 2010000203A HN 2010000203 A HN2010000203 A HN 2010000203A HN 2010000203 A HN2010000203 A HN 2010000203A HN 2010000203 A HN2010000203 A HN 2010000203A
Authority
HN
Honduras
Prior art keywords
compositions
arilamino
methods
sulfonamids
polymorphes
Prior art date
Application number
HN2010000203A
Other languages
Spanish (es)
Inventor
Vernier Jean-Michel
Edward Rowlings Colin
Luc Girardet Jean
Dimock Stuart
Quart Barry
Miner Jeffrey
Original Assignee
Ardea Bioscinences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40304796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HN2010000203(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/830,733 external-priority patent/US8101799B2/en
Application filed by Ardea Bioscinences Inc filed Critical Ardea Bioscinences Inc
Publication of HN2010000203A publication Critical patent/HN2010000203A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/28—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N41/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom
    • A01N41/02—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom containing a sulfur-to-oxygen double bond
    • A01N41/04—Sulfonic acids; Derivatives thereof
    • A01N41/06—Sulfonic acid amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Dentistry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Wood Science & Technology (AREA)

Abstract

ESTA INVENCION SE RELACIONA CON COMPUESTOS N-(2 ARILAMINO) ARIL SULFONAMIDA QUE SON INHIBIDORES DE MEK INCLUYENDO FORMAS POLIMORFICAS CRISTALINAS QUE EXHIBEN UN PERFIL DE DIFRACCION DE RAYOS X EN POLVO ESPECIFICO Y/O UN PERFIL QUE COMPRENDEN LOS COMPUESTOS DESCRITOS Y METODOS DE USO DE LOS COMPUESTOS Y COMPOSICIONES DESCRITOS INCLUYENDO EL USO EN EL TRATAMIENTO Y O PREVENCION DE CANCER, ENFERMEDADES HIPERPOROLIFERATIVAS Y CONDICIONES INFLAMATORIAS. LA INVENCION TAMBIEN SE RELACIONA CON METODOS PARA OBTENER LOS COMPUESTOS Y COMPOSICIONES QUE SE DESCRIBEN.THIS INVENTION IS RELATED TO N- (2 ARILAMINO) ARIL SULFONAMIDA COMPOUNDS THAT ARE INHIBITORS OF MEK INCLUDING CRYSTALLINE POLYMORPHIC FORMS THAT DISPLAY A SPECIFIC POWDER X-RAY PROFILE AND / OR A METHOD OF USE THE COMPOUNDS AND COMPOSITIONS DESCRIBED INCLUDING THE USE IN THE TREATMENT AND PREVENTION OF CANCER, HYPERPOROLIFERATIVE DISEASES AND INFLAMMATORY CONDITIONS. THE INVENTION IS ALSO RELATED TO METHODS TO OBTAIN THE COMPOUNDS AND COMPOSITIONS THAT ARE DESCRIBED.

HN2010000203A 2007-07-30 2010-01-29 DERIVATIVES OF N- (ARILAMINO) SULFONAMIDS THAT INCLUDE POLYMORPHES AS MEK INHIBITORS AS WELL AS COMPOSITIONS, METHODS OF PREPARATION USE OF THE SAME. HN2010000203A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/830,733 US8101799B2 (en) 2005-07-21 2007-07-30 Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
US3446408P 2008-03-06 2008-03-06
US3446608P 2008-03-06 2008-03-06
US4488608P 2008-04-14 2008-04-14

Publications (1)

Publication Number Publication Date
HN2010000203A true HN2010000203A (en) 2012-11-19

Family

ID=40304796

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2010000203A HN2010000203A (en) 2007-07-30 2010-01-29 DERIVATIVES OF N- (ARILAMINO) SULFONAMIDS THAT INCLUDE POLYMORPHES AS MEK INHIBITORS AS WELL AS COMPOSITIONS, METHODS OF PREPARATION USE OF THE SAME.

Country Status (22)

Country Link
EP (1) EP2184984A4 (en)
JP (3) JP2010535232A (en)
KR (3) KR20140098185A (en)
CN (2) CN103479604B (en)
AP (1) AP2817A (en)
AU (2) AU2008282338B2 (en)
BR (1) BRPI0815659A2 (en)
CA (1) CA2693390C (en)
CO (1) CO6470808A2 (en)
CR (1) CR11244A (en)
DO (1) DOP2010000045A (en)
EA (2) EA032294B1 (en)
EC (1) ECSP109910A (en)
HN (1) HN2010000203A (en)
IL (1) IL203296A (en)
MA (1) MA31881B1 (en)
MX (1) MX2010001244A (en)
NZ (1) NZ582929A (en)
PH (1) PH12015501914A1 (en)
SV (1) SV2010003469A (en)
TN (1) TN2010000049A1 (en)
WO (1) WO2009018233A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
CN102131771A (en) * 2008-04-14 2011-07-20 阿迪生物科学公司 Compositions and methods for preparing and using same
IL299322B2 (en) * 2008-09-09 2024-10-01 Hoffmann La Roche Pharmaceutical preparation of amorphous acyl sulfonamide
BRPI0919473A2 (en) 2008-09-26 2017-08-29 Oncomed Pharm Inc FRIZZLED BINDING AGENTS AND THEIR USES
AU2010224044A1 (en) 2009-03-11 2011-09-22 Ardea Biosciences, Inc. Pharmaceutical combinations comprising RDEA119/BAY 869766 for the treatment of specific cancers
UY32486A (en) * 2009-03-11 2010-10-29 Ardea Biosciences Inc TREATMENT OF CANCER CANCER
US9034861B2 (en) 2009-10-13 2015-05-19 Allomek Therapeutics Llc MEK inhibitors useful in the treatment of diseases
US8962606B2 (en) * 2009-10-21 2015-02-24 Bayer Intellectual Property Gmbh Substituted benzosulphonamides
TWI535445B (en) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Wnt antagonists and methods of treatment and screening
CN102020651B (en) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-aryl amino pyridone formamide MEK (methyl ethyl ketone) inhibitor
CN102649773A (en) * 2011-02-23 2012-08-29 苏州波锐生物医药科技有限公司 Amino aromatic hydrocarbon compound and application thereof to preparation of medicine for resisting malignant tumor
JP6363502B2 (en) * 2011-04-28 2018-07-25 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ HSP90 combination therapy
MX362823B (en) * 2011-05-27 2019-02-18 Ardea Biosciences Inc Star Chiral synthesis of n-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)ami no]-6-methoxyphenyl}-1-[2,3-dihydroxy-propyl]cyclopropanesulfona mides.
EP2788378A4 (en) * 2011-12-09 2015-09-09 Oncomed Pharm Inc ASSOCIATION THERAPY FOR THE TREATMENT OF CANCER
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
EP2854779A1 (en) * 2012-05-31 2015-04-08 Bayer Pharma Aktiengesellschaft Biomarkers for determining effective response of treatments of hepatocellular carcinoma (hcc) patients
BR112014030424A8 (en) 2012-06-04 2017-07-11 Pharmacyclics Inc CRYSTALLINE FORMS OF A BRUTON TYROSINE KINASE INHIBITOR
FI3702351T3 (en) * 2012-10-19 2024-01-24 Array Biopharma Inc Formulation comprising a mek inhibitor
EP2916859B1 (en) 2012-11-02 2017-06-28 The U.S.A. as represented by the Secretary, Department of Health and Human Services Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor
AU2014212081A1 (en) 2013-02-04 2015-08-13 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
EP2848246A1 (en) 2013-09-13 2015-03-18 Bayer Pharma Aktiengesellschaft Pharmaceutical compositions containing refametinib
WO2015041533A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
WO2015156674A2 (en) 2014-04-10 2015-10-15 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
WO2015196072A2 (en) 2014-06-19 2015-12-23 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
US11197896B2 (en) * 2014-08-25 2021-12-14 Société des Produits Nestlé S.A. Egg protein formulations and methods of manufacture thereof
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of proton tyrosine kinase inhibitor
BR112019026483A2 (en) 2017-06-16 2020-07-14 Beta Pharma, Inc. pharmaceutical formulation of n- (2- (2- (dimethylamine) ethoxy) -4-methoxy-5 - ((4- (1-methyl-1h-indol-3-yl) pyrimidin-2-yl) amine) phenyl) acrylamide and its salts
JP2022526713A (en) 2019-03-21 2022-05-26 オンクセオ Dbait molecule in combination with a kinase inhibitor for the treatment of cancer
JP2022551439A (en) * 2019-10-04 2022-12-09 スミトモ ファーマ オンコロジー， インコーポレイテッド AXL inhibitor formulation
JP2023500906A (en) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） Methods of treating cancers with acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma
CN118834328B (en) * 2024-07-02 2025-09-16 江苏海洋大学 Preparation method and application of metalloprotease 9 epitope imprinting nano-particles

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162117A (en) * 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
JP2575590B2 (en) * 1992-07-31 1997-01-29 塩野義製薬株式会社 Triazolylthiomethylthiocephalosporin hydrochloride and its hydrate crystals and their preparation
KR100296463B1 (en) * 1992-08-25 2001-10-24 죤 에이치. 뷰센 Hydroxyethylaminosulfonamide Useful as Retroviral Protease Inhibitor
US7115632B1 (en) * 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
EP1144394B1 (en) * 1999-01-13 2005-08-24 Warner-Lambert Company LLC 1-heterocycle substituted diarylamines
GB0003224D0 (en) * 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
CA2461227C (en) * 2001-09-24 2012-05-15 Jessie L.-S Au Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy
KR20050040907A (en) * 2002-07-17 2005-05-03 타이탄 파머슈티컬즈 인코퍼레이티드 Combination of chemotherapeutic drugs for increasing antitumor activity
JP2005535688A (en) * 2002-07-30 2005-11-24 ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング Use of alkylphosphocholines in combination with antitumor drugs
EP1871345B1 (en) * 2005-04-12 2012-08-01 Elan Pharma International Limited Nanoparticulate erlotinib formulations
WO2006115154A1 (en) * 2005-04-22 2006-11-02 Kissei Pharmaceutical Co., Ltd. Crystal polymorphism of 4’-{2-[(1s,2r)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethylamino]ethoxy}-3-isopropyl-3’,5’-dimethylbiphenylcarboxylic acid hydrochloride
CA2618218C (en) * 2005-07-21 2015-06-30 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of mek
JP2007099763A (en) * 2005-09-08 2007-04-19 Toyama Chem Co Ltd Novel crystals of piperacillin sodium monohydrate and process for producing the same
TW200800150A (en) * 2005-12-21 2008-01-01 Organon Nv Compounds with medicinal effects due to interaction with the glucocorticoid receptor

Also Published As

Publication number Publication date
EA201400552A1 (en) 2014-09-30
JP2010535232A (en) 2010-11-18
AP2817A (en) 2013-12-31
DOP2010000045A (en) 2010-10-31
EA020624B1 (en) 2014-12-30
IL203296A (en) 2017-06-29
SV2010003469A (en) 2010-04-30
KR20100092424A (en) 2010-08-20
AU2008282338A1 (en) 2009-02-05
AP2010005134A0 (en) 2010-02-28
JP2017125021A (en) 2017-07-20
NZ582929A (en) 2012-03-30
EP2184984A1 (en) 2010-05-19
CN101808516B (en) 2013-08-28
CN101808516A (en) 2010-08-18
CA2693390C (en) 2017-01-17
CN103479604A (en) 2014-01-01
AU2015200390B2 (en) 2017-02-23
EP2184984A4 (en) 2013-07-24
TN2010000049A1 (en) 2011-09-26
CR11244A (en) 2010-05-20
AU2008282338B2 (en) 2015-02-12
WO2009018233A1 (en) 2009-02-05
CO6470808A2 (en) 2012-06-29
HK1147396A1 (en) 2011-08-12
ECSP109910A (en) 2010-04-30
EA201000268A1 (en) 2010-08-30
JP2015078199A (en) 2015-04-23
CA2693390A1 (en) 2009-02-05
MA31881B1 (en) 2010-12-01
MX2010001244A (en) 2010-08-31
KR20140098185A (en) 2014-08-07
KR20150091434A (en) 2015-08-10
EA032294B1 (en) 2019-05-31
CN103479604B (en) 2016-08-10
BRPI0815659A2 (en) 2014-09-30
PH12015501914A1 (en) 2017-07-31
JP6309880B2 (en) 2018-04-11

Similar Documents

Publication Publication Date Title
HN2010000203A (en) DERIVATIVES OF N- (ARILAMINO) SULFONAMIDS THAT INCLUDE POLYMORPHES AS MEK INHIBITORS AS WELL AS COMPOSITIONS, METHODS OF PREPARATION USE OF THE SAME.
CR10304A (en) TETRAHYDROPIRIDOTIENOPIRIMIDINE COMPOUNDS AND PROCEDURES FOR THE SAME USE
UY29375A1 (en) 5-ALCOXIALQUIL-6-ALQUIL-7-AMINO-AZOLOPIRIMIDINAS, A PROCEDURE FOR ITS OBTAINING AND THE USE OF THE SAME TO COMBAT HARMFUL FUNGES, AS WELL AS PRODUCTS THAT CONTAIN THEM.
CL2019001993A1 (en) Selective inhibitors of jak1.
HN2012001162A (en) TRIAZOLOPIRIDINS
UY32611A (en) 1-CYANOETHYLETHYCLIC CARBOXAMIDE SUBSTITUTED COMPOUNDS 750
PA8593001A1 (en) PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH
UY28708A1 (en) REPLACED HETEROCICLES AND USES OF THE SAME
CL2008002295A1 (en) Alkylsulfonyl-substituted thiazolid derivative compounds; pharmaceutical composition; and use for the treatment of hepatitis c.
GT200500325A (en) PIRAZOLO-PIRIMIDINAS 1,4-REPLACED AS QUINASA INHIBITORS
UY30748A1 (en) NEW COMPOUNDS
CR11861A (en) ORGANIC COMPOUNDS
CO6361927A2 (en) PDK1 QUINAZOLINES FOR INHIBITION
MX2015011311A (en) New octahydro-pyrrolo[3,4-c]-pyrrole derivatives and analogs thereof as autotaxin inhibitors.
UY31524A1 (en) NEW COMPOUNDS 010
UY29795A1 (en) ADENINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCESSES AND APPLICATIONS
ECSP099822A (en) POLICYCLE GUANINE DERIVATIVES AND THEIR METHODS OF USE
CO6361849A2 (en) DERIVATIVES OF N-CICLOALQUIL-NBIFENILMETIL-CARBOXAMIDA FUNGICIDAS
CR11098A (en) PIRIDO COMPOUNDS [2,3-D] PIRIMIDINA-7-ONA AS P13K-ALFA INHIBITORS FOR CANCER TREATMENT
GT200600013A (en) ORGANIC COMPOUNDS
DOP2020000100A (en) NOVEL PYRAZOLO-PIRROLO-PYRIMIDINE DERIVATIVES AS P2X3 INHIBITORS
UY29767A1 (en) BENZOTIAZOLONAS DERIVATIVES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND APPLICATIONS
DOP2006000061A (en) PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS
CR9257A (en) CCI-779 POLYMORPH AND USE OF IT
PA8589801A1 (en) AMINOALCOXYINDOLS